Challenges to accurate susceptibility testing and interpretation of quinolone resistance in Enterobacteriaceae: Results of a Spanish multicentre study

Journal of Antimicrobial Chemotherapy

Volumn 70, Issue 7, 2015, Pages 2038-2047

  Rodriguez Martinez, José Manuel ^a,b   Machuca, Jesús ^b,c   Calvo, Jorge ^d,e   Diaz de Alba, Paula ^a   Rodríguez Mirones, Cristina ^d   Gimeno, Concha ^f   Martinez Martinez, Luis ^d,e   Pascual, Álvaro ^a,b,c  

^a UNIVERSITY OF SEVILLE   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^d HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^e UNIVERSITY OF CANTABRIA   (Spain)

^f HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

Author keywords

Aac(6') Ib cr; Efflux pumps; OqxAB; Porins; QepA; Qnr; QRDR

Indexed keywords

CIPROFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; NALIDIXIC ACID; NORFLOXACIN; OFLOXACIN; QUINOLONE; QUINOLONE DERIVATIVE;

ACCURACY; ANALYTICAL ERROR; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; CONSENSUS; CONTROLLED STUDY; ENTEROBACTERIACEAE; GENE MUTATION; INHIBITION ZONE; MINIMUM INHIBITORY CONCENTRATION; MULTICENTER STUDY; NONHUMAN; PHENOTYPE;

EID: 84936934325     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkv059     Document Type: Article

References (33)

1. Drlica K, Hiasa H, Kerns R et al. Quinolones: action and resistance updated. Curr Top Med Chem 2009; 9: 981-98.
2. Singh R, Swick MC, Ledesma KR et al. Temporal interplay between efflux pumps and target mutations in development of antibiotic resistance in Escherichia coli. Antimicrob Agents Chemother 2012; 56: 1680-5.
3. Strahilevitz J, Jacoby GA, Hooper DC et al. Plasmid-mediated quinolone resistance: a multifaceted threat. Clin Microbiol Rev 2009; 22: 664-89.
4. Rodriguez-Martinez JM, Cano ME, Velasco C et al. Plasmid-mediated quinolone resistance: an update. J Infect Chemother 2011; 17: 149-82.
5. Fraimow H, Nahra R. Resistant Gram-negative infections. Crit Care Clin 2013; 29: 895-921.
6. Paterson DL. Impact of antibiotic resistance in Gram-negative bacilli on empirical and definitive antibiotic therapy. Clin Infect Dis 2008; 47 Suppl 1: S14-20.
7. Woodford N, Eastaway AT, FordM et al. Comparison of BDPhoenix, Vitek 2, and MicroScan automated systems for detection and inference of mechanisms responsible for carbapenem resistance in Enterobacteriaceae. J Clin Microbiol 2010; 48: 2999-3002.
8. Canton R, Loza E, Del Carmen ConejoMet al. Quality control for β-lactam susceptibility testing with a well-defined collection of Enterobacteriaceae and Pseudomonas aeruginosa strains in Spain. J Clin Microbiol 2003; 41: 1912-8.
9. Juan C, Conejo MC, Tormo N et al. Challenges for accurate susceptibility testing, detection and interpretation of β-lactam resistance phenotypes in Pseudomonas aeruginosa: results from a Spanish multicentre study. J Antimicrob Chemother 2013; 68: 619-30.
10. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Twenty-fourth Informational Supplement M100-S24. CLSI, Wayne, PA, USA, 2014.
11. EUCAST. Clinical Breakpoints and Epidemiological Cut-off Values. 2014. http://www.eucast.org/clinical_breakpoints/.
12. Camaro-Sala ML, Martinez-Garcia R, Olmos-Martinez P et al. Validation and verification of microbiology methods. Enferm Infecc Microbiol Clin 2014; doi:10.1016/j.eimc.2013.11.010.
13. Hooper DC. Emerging mechanisms of fluoroquinolone resistance. Emerg Infect Dis 2001; 7: 337-41.
14. Jacoby GA. Mechanisms of resistance to quinolones. Clin Infect Dis 2005; 41 Suppl 2: S120-6.
15. Martinez-Martinez L, Pascual A, Canton R. The Spanish antibiogram committee (COESANT), in step with EUCAST. Enferm Infecc Microbiol Clin 2013; 31: 639-40.
16. Rodriguez-Martinez JM, Briales A, Velasco C et al. Discrepancies in fluoroquinolone clinical categories between the European Committee on Antimicrobial Susceptibility Testing (EUCAST) and CLSI for Escherichia coli harbouring qnr genes and mutations in gyrA and parC. J Antimicrob Chemother 2011; 66: 1405-7.
17. Poirel L, Pitout JD, Calvo L et al. In vivo selection of fluoroquinoloneresistant Escherichia coli isolates expressing plasmid-mediated quinolone resistance and expanded-spectrum β-lactamase. Antimicrob Agents Chemother 2006; 50: 1525-7.
18. Schentag JJ, Meagher AK, Forrest A. Fluoroquinolone AUIC break points and the link to bacterial killing rates. Part 2: human trials. Ann Pharmacother 2003; 37: 1478-88.
19. Machuca J, Briales A, Labrador G et al. Interplay between plasmidmediated and chromosomal-mediated fluoroquinolone resistance and bacterial fitness in Escherichia coli. J Antimicrob Chemother 2014; 69: 3203-15.
20. Cavaco LM, Aarestrup FM. Evaluation of quinolones for use in detection of determinants of acquired quinolone resistance, including the new transmissible resistance mechanisms qnrA, qnrB, qnrS, and aac(6')Ib-cr, in Escherichia coli and Salmonella enterica and determinations of wild-type distributions. J Clin Microbiol 2009; 47: 2751-8.
21. Corvec S, Cremet L, Reynaud A et al. Vitek2 system: a reliable tool to detect qnr determinants in Enterobacteriaceae without quinolone resistance-determining region modifications. Diagn Microbiol Infect Dis 2009; 64: 455-7.
22. Lupo A, Papp-Wallace KM, Sendi P et al. Non-phenotypic tests to detect and characterize antibiotic resistance mechanisms in Enterobacteriaceae. Diagn Microbiol Infect Dis 2013; 77: 179-94.
23. Calvo J, Cano ME, Pitart C et al. Evaluation of three automated systems for susceptibility testing of Enterobacteria containing qnrB, qnrS, and/or aac(6')-Ib-cr. J Clin Microbiol 2011; 49: 3343-5.
24. Rodriguez-Martinez JM, Conejo MC, Martinez-Martinez L et al. Evaluation of antimicrobial susceptibility of bacteria containing the qnr gene and FOX-5 β-lactamase by four automated systems. Clin Microbiol Infect 2005; 11: 402-4.
25. Rodriguez-Martinez JM, Pichardo C, Garcia I et al. Activity of ciprofloxacin and levofloxacin in experimental pneumonia caused by Klebsiella pneumoniae deficient in porins, expressing active efflux and producing QnrA1. Clin Microbiol Infect 2008; 14: 691-7.
26. Guillard T, Cambau E, Chau F et al. Ciprofloxacin treatment failure in a murine model of pyelonephritis due to an AAC(6')-Ib-cr-producing Escherichia coli strain susceptible to ciprofloxacin in vitro. Antimicrob Agents Chemother 2013; 57: 5830-5.
27. Ruiz E, Ocampo-Sosa AA, Alcoba-Florez J et al. Changes in ciprofloxacin resistance levels in Enterobacter aerogenes isolates associated with variable expression of the aac(6')-Ib-cr gene. Antimicrob Agents Chemother 2012; 56: 1097-100.
28. Cano ME, Calvo J, Agüero J et al. Plasmid-mediated quinolone resistance among enterobacteria with reduced susceptibility or resistance to ciprofloxacin but susceptible to nalidixic acid. In: Abstracts of the Forty-seventh Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 2007. Abstract C2-152, p. 103. American Society for Microbiology, Washington, DC, USA.
29. Ruiz E, Saenz Y, Zarazaga M et al. qnr, aac(6')-Ib-cr and qepA genes in Escherichia coli and Klebsiella spp.: Genetic environments and plasmid and chromosomal location. J Antimicrob Chemother 2012; 67: 886-97.
30. Martinez-Martinez L, Hernandez-Alles S, Alberti S et al. In vivo selection of porin-deficient mutants of Klebsiella pneumoniae with increased resistance to cefoxitin and expanded-spectrum-cephalosporins. Antimicrob Agents Chemother 1996; 40: 342-8.
31. Martinez-Martinez L, Garcia I, Ballesta S et al. Energy-dependent accumulation of fluoroquinolones in quinolone-resistant Klebsiella pneumoniae strains. Antimicrob Agents Chemother 1998; 42: 1850-2.
32. Lopez-Cerero L, Bellido MM, Serrano L et al. Escherichia coli O25b:H4/ ST131 are prevalent in Spain and are often not associated with ESBL or quinolone resistance. Enferm Infecc Microbiol Clin 2013; 31: 385-8.
33. Elder BL, Hansen SA, Kellogg JA et al. Verification and Validation of Procedures in the Clinical Microbiology Laboratory. In: McCurdy BW, ed. CUMITECH: Cumulative Techniques and Procedures in Clinical Microbiology. Washington, DC: American Society for Microbiology, 1997.